The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Life Science CDMO Market Research Report 2024
Synopsis
The global Life Science CDMO market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Life Science CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Life Science CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Life Science CDMO in Pharmaceutical is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Life Science CDMO include Lonza Group, Thermo Fisher Scientific, Catalent, WuXi Biologics, Samsung Biologics, Siegfried, Fujifilm Diosynth Biotechnologies, Lars Petersen and Recipharm, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Life Science CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Life Science CDMO.
Report Scope
The Life Science CDMO market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Life Science CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Life Science CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Lonza Group
Thermo Fisher Scientific
Catalent
WuXi Biologics
Samsung Biologics
Siegfried
Fujifilm Diosynth Biotechnologies
Lars Petersen
Recipharm
Boehringer Ingelheim
MilliporeSigma
Aenova Group
AGC Parma Chemicals
GenScript
Novartis
Sai Life Sciences
Segment by Type
Active Pharmaceutical Ingredient (API) CDMO
Biologics CDMO
Finished Dosage Form (FDF) CDMO
Others
Segment by Application
Pharmaceutical
Clinical
Research
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Life Science CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Life Science CDMO market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Life Science CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Life Science CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Life Science CDMO in Pharmaceutical is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Life Science CDMO include Lonza Group, Thermo Fisher Scientific, Catalent, WuXi Biologics, Samsung Biologics, Siegfried, Fujifilm Diosynth Biotechnologies, Lars Petersen and Recipharm, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Life Science CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Life Science CDMO.
Report Scope
The Life Science CDMO market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Life Science CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Life Science CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Lonza Group
Thermo Fisher Scientific
Catalent
WuXi Biologics
Samsung Biologics
Siegfried
Fujifilm Diosynth Biotechnologies
Lars Petersen
Recipharm
Boehringer Ingelheim
MilliporeSigma
Aenova Group
AGC Parma Chemicals
GenScript
Novartis
Sai Life Sciences
Segment by Type
Active Pharmaceutical Ingredient (API) CDMO
Biologics CDMO
Finished Dosage Form (FDF) CDMO
Others
Segment by Application
Pharmaceutical
Clinical
Research
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Life Science CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Life Science CDMO Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Active Pharmaceutical Ingredient (API) CDMO
1.2.3 Biologics CDMO
1.2.4 Finished Dosage Form (FDF) CDMO
1.2.5 Others
1.3 Market by Application
1.3.1 Global Life Science CDMO Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Pharmaceutical
1.3.3 Clinical
1.3.4 Research
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Life Science CDMO Market Perspective (2019-2030)
2.2 Life Science CDMO Growth Trends by Region
2.2.1 Global Life Science CDMO Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Life Science CDMO Historic Market Size by Region (2019-2024)
2.2.3 Life Science CDMO Forecasted Market Size by Region (2025-2030)
2.3 Life Science CDMO Market Dynamics
2.3.1 Life Science CDMO Industry Trends
2.3.2 Life Science CDMO Market Drivers
2.3.3 Life Science CDMO Market Challenges
2.3.4 Life Science CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Life Science CDMO Players by Revenue
3.1.1 Global Top Life Science CDMO Players by Revenue (2019-2024)
3.1.2 Global Life Science CDMO Revenue Market Share by Players (2019-2024)
3.2 Global Life Science CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Life Science CDMO Revenue
3.4 Global Life Science CDMO Market Concentration Ratio
3.4.1 Global Life Science CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Life Science CDMO Revenue in 2023
3.5 Life Science CDMO Key Players Head office and Area Served
3.6 Key Players Life Science CDMO Product Solution and Service
3.7 Date of Enter into Life Science CDMO Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Life Science CDMO Breakdown Data by Type
4.1 Global Life Science CDMO Historic Market Size by Type (2019-2024)
4.2 Global Life Science CDMO Forecasted Market Size by Type (2025-2030)
5 Life Science CDMO Breakdown Data by Application
5.1 Global Life Science CDMO Historic Market Size by Application (2019-2024)
5.2 Global Life Science CDMO Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Life Science CDMO Market Size (2019-2030)
6.2 North America Life Science CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Life Science CDMO Market Size by Country (2019-2024)
6.4 North America Life Science CDMO Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Life Science CDMO Market Size (2019-2030)
7.2 Europe Life Science CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Life Science CDMO Market Size by Country (2019-2024)
7.4 Europe Life Science CDMO Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Life Science CDMO Market Size (2019-2030)
8.2 Asia-Pacific Life Science CDMO Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Life Science CDMO Market Size by Region (2019-2024)
8.4 Asia-Pacific Life Science CDMO Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Life Science CDMO Market Size (2019-2030)
9.2 Latin America Life Science CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Life Science CDMO Market Size by Country (2019-2024)
9.4 Latin America Life Science CDMO Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Life Science CDMO Market Size (2019-2030)
10.2 Middle East & Africa Life Science CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Life Science CDMO Market Size by Country (2019-2024)
10.4 Middle East & Africa Life Science CDMO Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lonza Group
11.1.1 Lonza Group Company Detail
11.1.2 Lonza Group Business Overview
11.1.3 Lonza Group Life Science CDMO Introduction
11.1.4 Lonza Group Revenue in Life Science CDMO Business (2019-2024)
11.1.5 Lonza Group Recent Development
11.2 Thermo Fisher Scientific
11.2.1 Thermo Fisher Scientific Company Detail
11.2.2 Thermo Fisher Scientific Business Overview
11.2.3 Thermo Fisher Scientific Life Science CDMO Introduction
11.2.4 Thermo Fisher Scientific Revenue in Life Science CDMO Business (2019-2024)
11.2.5 Thermo Fisher Scientific Recent Development
11.3 Catalent
11.3.1 Catalent Company Detail
11.3.2 Catalent Business Overview
11.3.3 Catalent Life Science CDMO Introduction
11.3.4 Catalent Revenue in Life Science CDMO Business (2019-2024)
11.3.5 Catalent Recent Development
11.4 WuXi Biologics
11.4.1 WuXi Biologics Company Detail
11.4.2 WuXi Biologics Business Overview
11.4.3 WuXi Biologics Life Science CDMO Introduction
11.4.4 WuXi Biologics Revenue in Life Science CDMO Business (2019-2024)
11.4.5 WuXi Biologics Recent Development
11.5 Samsung Biologics
11.5.1 Samsung Biologics Company Detail
11.5.2 Samsung Biologics Business Overview
11.5.3 Samsung Biologics Life Science CDMO Introduction
11.5.4 Samsung Biologics Revenue in Life Science CDMO Business (2019-2024)
11.5.5 Samsung Biologics Recent Development
11.6 Siegfried
11.6.1 Siegfried Company Detail
11.6.2 Siegfried Business Overview
11.6.3 Siegfried Life Science CDMO Introduction
11.6.4 Siegfried Revenue in Life Science CDMO Business (2019-2024)
11.6.5 Siegfried Recent Development
11.7 Fujifilm Diosynth Biotechnologies
11.7.1 Fujifilm Diosynth Biotechnologies Company Detail
11.7.2 Fujifilm Diosynth Biotechnologies Business Overview
11.7.3 Fujifilm Diosynth Biotechnologies Life Science CDMO Introduction
11.7.4 Fujifilm Diosynth Biotechnologies Revenue in Life Science CDMO Business (2019-2024)
11.7.5 Fujifilm Diosynth Biotechnologies Recent Development
11.8 Lars Petersen
11.8.1 Lars Petersen Company Detail
11.8.2 Lars Petersen Business Overview
11.8.3 Lars Petersen Life Science CDMO Introduction
11.8.4 Lars Petersen Revenue in Life Science CDMO Business (2019-2024)
11.8.5 Lars Petersen Recent Development
11.9 Recipharm
11.9.1 Recipharm Company Detail
11.9.2 Recipharm Business Overview
11.9.3 Recipharm Life Science CDMO Introduction
11.9.4 Recipharm Revenue in Life Science CDMO Business (2019-2024)
11.9.5 Recipharm Recent Development
11.10 Boehringer Ingelheim
11.10.1 Boehringer Ingelheim Company Detail
11.10.2 Boehringer Ingelheim Business Overview
11.10.3 Boehringer Ingelheim Life Science CDMO Introduction
11.10.4 Boehringer Ingelheim Revenue in Life Science CDMO Business (2019-2024)
11.10.5 Boehringer Ingelheim Recent Development
11.11 MilliporeSigma
11.11.1 MilliporeSigma Company Detail
11.11.2 MilliporeSigma Business Overview
11.11.3 MilliporeSigma Life Science CDMO Introduction
11.11.4 MilliporeSigma Revenue in Life Science CDMO Business (2019-2024)
11.11.5 MilliporeSigma Recent Development
11.12 Aenova Group
11.12.1 Aenova Group Company Detail
11.12.2 Aenova Group Business Overview
11.12.3 Aenova Group Life Science CDMO Introduction
11.12.4 Aenova Group Revenue in Life Science CDMO Business (2019-2024)
11.12.5 Aenova Group Recent Development
11.13 AGC Parma Chemicals
11.13.1 AGC Parma Chemicals Company Detail
11.13.2 AGC Parma Chemicals Business Overview
11.13.3 AGC Parma Chemicals Life Science CDMO Introduction
11.13.4 AGC Parma Chemicals Revenue in Life Science CDMO Business (2019-2024)
11.13.5 AGC Parma Chemicals Recent Development
11.14 GenScript
11.14.1 GenScript Company Detail
11.14.2 GenScript Business Overview
11.14.3 GenScript Life Science CDMO Introduction
11.14.4 GenScript Revenue in Life Science CDMO Business (2019-2024)
11.14.5 GenScript Recent Development
11.15 Novartis
11.15.1 Novartis Company Detail
11.15.2 Novartis Business Overview
11.15.3 Novartis Life Science CDMO Introduction
11.15.4 Novartis Revenue in Life Science CDMO Business (2019-2024)
11.15.5 Novartis Recent Development
11.16 Sai Life Sciences
11.16.1 Sai Life Sciences Company Detail
11.16.2 Sai Life Sciences Business Overview
11.16.3 Sai Life Sciences Life Science CDMO Introduction
11.16.4 Sai Life Sciences Revenue in Life Science CDMO Business (2019-2024)
11.16.5 Sai Life Sciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest IT & Electronics Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
